Extended Data Fig. 8: Affinity and Epitope targeting of anti-SARS-CoV-2 RBD antibodies.

a, IC₅₀ values for randomly selected antibodies isolated from convalescents 1.3m³ (n=42) and 6.2m⁷ (n=45) after infection or from vaccinees after prime (n=36), and 1.3m (n=74) and 5m (n=43). Red horizontal lines and numbers indicate geometric mean. Antibodies isolated from samples without a prime value are shown in black. b, Graphs show affinities (K_D, Y-axis) plotted against neutralization activity (IC₅₀, X-axis) for antibodies isolated after prime (black), or 1.3m (orange) or 5m (green) post-boost vaccination for antibodies showin in a. c, Schematic representation of the BLI experiment for randomly selected antibodies isolated from vaccinees 1.3- and 5 months after full vaccination (each presented group shows n=26 antibodies). d. Heat-map of relative inhibition of Ab2 binding to the preformed Ab1-RBD complexes (grey=no binding, yellow=low binding, orange=intermediate binding, red=high binding). Values are normalized through the subtraction of the autologous antibody control. BLI traces can be found in Extended Data Fig. 9. e. Pie charts indicate the fraction of antibodies that are assigned to different classes according to their binding pattern as shown in d and Extended data Fig. 9. Number in inner circle shows number of antibodies tested. Statistical significance was determined using a two-tailed Kruskal Wallis test with subsequent Dunn’s multiple comparisons in a and two-tailed Spearman correlation test in b, and a two-tailed Chi-square test in e.